Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.
19891.2k citationsShin Yonehara, A Ishii et al.The Journal of Experimental Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of A Ishii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Ishii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Ishii more than expected).
This network shows the impact of papers produced by A Ishii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Ishii. The network helps show where A Ishii may publish in the future.
Co-authorship network of co-authors of A Ishii
This figure shows the co-authorship network connecting the top 25 collaborators of A Ishii.
A scholar is included among the top collaborators of A Ishii based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with A Ishii. A Ishii is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Oh, Hannah, et al.. (1994). [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].. PubMed. 35(9). 846–52.3 indexed citations
7.
Nakaseko, Chiaki, et al.. (1993). [Prostaglandin E1 bladder instillations for a patient with severe hemorrhagic cystitis after allogeneic bone marrow transplantation].. PubMed. 34(6). 769–72.1 indexed citations
8.
Nakamura, Hirotoshi, Chiaki Nakaseko, A Ishii, et al.. (1993). [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6].. PubMed. 34(2). 212–7.10 indexed citations
9.
Mizushima, Yutaka, et al.. (1991). Effect of leukotriene antagonist on experimental and clinical bronchial asthma.. PubMed. 21A. 465–8.5 indexed citations
Yonehara, Shin, et al.. (1989). A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.. The Journal of Experimental Medicine. 169(5). 1747–1756.1234 indexed citations breakdown →
Ishii, A, Masashi Matsui, Yoshitake Terano, & Yoshihide Miura. (1988). Establishment and characterization of a novel human malignant melanoma cell line AKI.. PubMed. 34(3). 255–64.2 indexed citations
15.
Saida, Toshiaki, A Ishii, Iwao Ando, et al.. (1985). [Establishment of a human melanoma cell line and its cytological characteristics].. PubMed. 95(1). 31–41.1 indexed citations
Ishii, A. (1973). Indirect fluorescent antibody test in human sparganosis.. Kiseichūgaku zasshi. 22(2). 75–78.4 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.